We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Qure’s aim is to provide individual healthcare that is both affordable and highly convenient, becoming the platform of choice for both patients and practitioners. Qure offer 24/7 private healthcare, without the huge price tag that is usually associated with these kinds of services. 
days to go: Expired investment: £1,162,206
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £286,992
Ultramed are a health tech company, placing patient experience and innovation at the forefront. They operate a suite of cloud based pre operative products by combining clinical NHS operative experience. The aim is to reduce costs increase health care resources.
days to go: Expired investment: £317,540
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
days to go: Expired investment: £251,600
The British Journal of Photography (BJP) is a monthly magazine dedicated to comtemporary photography. In the last 3 years, the print magazine has been completely re-designed and since then, BJP have launched new apps, new events and awards aimed at capturing the next generation of readers. 
days to go: Expired investment: £399,720
DotFrames is pioneering an AI, VR, and AR-powered e-commerce platform for immersive 3D experiences. Their focus is on media and entertainment, creating hyper-real galleries for art and collectibles. They aim to develop a next-gen Shopify platform-as-a-service, enabling clients to showcase and sell various products in immersive environments. The investment will fuel platform development. DotFrames merges technology and artistry, reshaping art appreciation.
days to go: Expired investment: £100,000
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go: Expired investment: £543,670
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph